Comparison of Humoral and Cellular CMV Immunity in Patients Awaiting Kidney Transplantation
暂无分享,去创建一个
A. Kribben | U. Eisenberger | O. Witzke | P. Horn | U. Dittmer | B. Wilde | M. Lindemann | J. Friebus-Kardash | A. Gäckler | N. Mülling
[1] P. Horn,et al. Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients , 2021, Vaccines.
[2] Mark M. Davis,et al. Aging and CMV discordance are associated with increased immune diversity between monozygotic twins , 2021, Immunity & Ageing.
[3] S. Koo,et al. Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events , 2020, BMC Infectious Diseases.
[4] W. Guo,et al. Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation , 2019, Medicine.
[5] A. Mehta,et al. A prospective multicenter observational study of cell‐mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] Su Jin Lee,et al. CMV specific T cell immunity predicts early viremia after liver transplantation. , 2018, Transplant immunology.
[7] O. Witzke,et al. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. , 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[8] M. John,et al. Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia. , 2018, Pathology.
[9] P. Saas,et al. ESRD-associated immune phenotype depends on dialysis modality and iron status: clinical implications , 2018, Immunity & ageing : I & A.
[10] B. Banas,et al. Clinical validation of a novel enzyme‐linked immunosorbent spot assay‐based in vitro diagnostic assay to monitor cytomegalovirus‐specific cell‐mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study , 2018, Transplant international : official journal of the European Society for Organ Transplantation.
[11] R. Borrows,et al. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study , 2018, PloS one.
[12] L. Potena,et al. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection , 2018, Journal of Clinical Microbiology.
[13] J. Kwekkeboom,et al. Protective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney Transplant Patients without Serum Anti-CMV Antibodies , 2017, Front. Immunol..
[14] Deepali Kumar,et al. An Interventional Study Using Cell‐Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[15] R. Wagner,et al. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity , 2017, BMC Immunology.
[16] M. Jankowska,et al. CD28 positive, cytomegalovirus specific cytotoxic T lymphocytes as a novel biomarker associated with cytomegalovirus viremia in kidney allorecipients. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[17] H. Hirsch,et al. The “ABC” of Virus‐Specific T Cell Immunity in Solid Organ Transplantation , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[18] N. Mueller,et al. The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ Transplantation , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] C. Pannuti,et al. Cytomegalovirus infection in transplant recipients , 2015, Clinics.
[20] R. Razonable,et al. Cytomegalovirus infection in liver transplant recipients: updates on clinical management. , 2014, World journal of gastroenterology.
[21] M. Ison,et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Deepali Kumar,et al. Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia , 2012, Transplantation.
[23] W. Weimar,et al. Expansion of cytolytic CD4+CD28- T cells in end-stage renal disease. , 2008, Kidney international.
[24] R. Khanna,et al. Ex vivo monitoring of human cytomegalovirus‐specific CD8+ T‐cell responses using QuantiFERON®‐CMV , 2007, Transplant infectious disease : an official journal of the Transplantation Society.
[25] E. Kreuzfelder,et al. ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. , 2006, Clinical immunology.
[26] H. Schäfers,et al. Differences in CMV‐Specific T‐Cell Levels and Long‐Term Susceptibility to CMV Infection after Kidney, Heart and Lung Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[27] S. Seeber,et al. Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation , 2005, Leukemia.
[28] E. Tartour,et al. Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. , 2004, Human immunology.
[29] L. Korčáková. [Cytomegalovirus antibodies: review of results of repeated examinations in 208 hemodialyzed patients]. , 1995, Vnitrni lekarstvi.
[30] O Ouchterlony,et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. , 1988, Journal of immunological methods.
[31] B. Banas,et al. Clinical validation of T-track (R) CMV to assess the functionality of cmv-specific cell-mediated immunity in kidney transplant recipients , 2016 .